Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet--NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue BMJ Open Année : 2015

Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet--NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial

David Balayssac
  • Fonction : Auteur
Jérémy Ferrier
  • Fonction : Auteur
Bruno Pereira
Brigitte Gillet
  • Fonction : Auteur
Caroline Petorin
  • Fonction : Auteur
Julie Vein
  • Fonction : Auteur
Frédéric Libert
  • Fonction : Auteur
Alain Eschalier
  • Fonction : Auteur
Denis Pezet
  • Fonction : Auteur

Résumé

Oxaliplatin remains the most widely used chemotherapeutic agent for treating advanced colorectal cancer but its efficacy is hampered by dose-limiting neurotoxicity manifested by a painful polyneuropathy. Oxaliplatin-induced peripheral neuropathy (OIPN) is characterised by acute and transient cold hyperaesthesia in the hours and days following oxaliplatin infusion (>90% of patients), but also by retarded chronic neuropathy due to the repetition of chemotherapy cycles (30-50% of patients). OIPN impairs the health-related quality of life (HRQOL) of patients and no preventive or curative strategies have as yet proven effective. A polyamine-reduced diet (PRD) has recently demonstrated its efficacy to prevent OIPN in animals without adverse effects.

Dates et versions

hal-04327774 , version 1 (06-12-2023)

Identifiants

Citer

David Balayssac, Jérémy Ferrier, Bruno Pereira, Brigitte Gillet, Caroline Petorin, et al.. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet--NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. BMJ Open, 2015, 5 (4), pp.e007479-e007479. ⟨10.1136/bmjopen-2014-007479⟩. ⟨hal-04327774⟩

Collections

PRES_CLERMONT ND
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More